Sandoz to acquire antifungal agent Mycamine from Astellas

24 January 2023
sandoz_big

Sandoz, the generic and biosimilar medicines business of Swiss pharma giant Novartis (NOVN: VX), has signed an agreement to acquire worldwide product rights for leading systemic antifungal agent Mycamine (micafungin sodium, trade named Funguard in Japan) from Astellas Pharma (TYO: 4503).

The deal is expected to close in the course of first-half 2023, subject to standard conditions and regulatory approvals.

Astellas reported Mycamine sales of 18.9 billion yen ($135 million) for the year ending March 31, 2022. The announcement comes after Sandoz, which Novartis plans to split out as a separate company,  successfully completed the acquisition of GSK’s global cephalosporins portfolio in October 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics